The outcomes of ICI treatment in four NFPAs were reviewed in a series of 13 patients with aggressive pituitary tumors and 16 patients with carcinomas treated with PD-1 inhibitors as a monotherapy or in conjunction with other ICIs. Here, PDCD1 is linked to pituitary tumor.